Study summary · research use only
Methylene Blue for Vasoplegic Syndrome
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This is a review discussing methylene blue (MB) as a therapy for vasoplegic syndrome, a form of vasodilatory shock occurring in patients undergoing cardiac surgery with cardiopulmonary bypass (CBP). The review states MB has become a popular therapy for cardiac vasoplegia despite limited prospective data supporting its use, and focuses on mechanisms, dosing strategies, and side effects of MB in this context. Species/population: human cardiac surgery patients, as described in the reviewed literature.
Abstract
Vasoplegic syndrome is a form of vasodilatory shock that occurs frequently in patients who undergo cardiac surgery requiring cardiopulmonary bypass (CBP). Treatment often demands high doses of vasopressors over sustained periods for hypotension that can be refractory to standard vasoactive medications. Furthermore, the development of vasoplegia greatly contributes to morbidity and mortality following cardiac surgery. Methylene blue (MB) has become a popular therapy for cardiac vasoplegia despite a paucity of prospective data to direct its use. Therefore, the aim of this study was to review available data regarding mechanisms, dosing strategies, and side effects of MB, with a focus on its applications for vasoplegia in cardiac surgery.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.